Access the full text.
Sign up today, get DeepDyve free for 14 days.
Sae-Won Han, Tae-You Kim, P. Hwang, Soohyun Jeong, Jeong-Whun Kim, I. Choi, D. Oh, J. Kim, Dong-Wan Kim, D. Chung, S. Im, Y. Kim, J. Lee, D. Heo, Y. Bang, N. Kim (2005)
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 11
J. Buter, G. Giaccone (2005)
EGFR inhibitors in lung cancer.Oncology, 19 13
T. Takano, Y. Ohe, H. Sakamoto, K. Tsuta, Y. Matsuno, U. Tateishi, Seiichiro Yamamoto, H. Nokihara, N. Yamamoto, I. Sekine, H. Kunitoh, T. Shibata, T. Sakiyama, Teruhiko Yoshida, T. Tamura (2005)
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 28
Amy Tai, J. Sham, D. Xie, Yan Fang, Yi-long Wu, Liang Hu, W. Deng, G. Tsao, G. Qiao, A. Cheung, X. Guan (2006)
Co‐overexpression of fibroblast growth factor 3 and epidermal growth factor receptor is correlated with the development of nonsmall cell lung carcinomaCancer, 106
H. Cortés-Funes, C. Gómez, R. Rosell, P. Valero, C. García-Girón, Ángela Velasco, A. Izquierdo, P. Diz, C. Camps, D. Castellanos, V. Alberola, F. Cardenal, J. González-Larriba, J. Viéitez, I. Maeztu, J. Sánchez, C. Queralt, C. Mayo, P. Méndez, T. Moran, M. Taron (2005)
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.Annals of oncology : official journal of the European Society for Medical Oncology, 16 7
F. Shepherd, J. Pereira, T. Ciuleanu, E. Tan, V. Hirsh, S. Thongprasert, D. Campos, Savitree Maoleekoonpiroj, M. Smylie, R. Martins, M. Kooten, M. Dediu, B. Findlay, D. Tu, D. Johnston, A. Bezjak, G. Clark, P. Santabarbara, L. Seymour (2005)
Erlotinib in previously treated non-small-cell lung cancer.The New England journal of medicine, 353 2
E. Conde, Bárbara Angulo, M. Tang, M. Morente, J. Torres-Lanzas, A. Lopez-Encuentra, F. López-Rios, M. Sanchez-Cespedes (2006)
Molecular Context of the EGFR Mutations: Evidence for the Activation of mTOR/S6K SignalingClinical Cancer Research, 12
Dacic (2006)
Significance of EGFR protein expression and gene amplification in non-small cell lung carcinomaAm J Clin Pathol, 125
S. Dacic, Melina Flanagan, K. Cieply, S. Ramalingam, J. Luketich, C. Belani, S. Yousem (2006)
Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma.American journal of clinical pathology, 125 6
F. Hirsch, P. Bunn (2005)
Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 36
T. Mitsudomi, T. Kosaka, H. Endoh, Y. Horio, T. Hida, S. Mori, S. Hatooka, M. Shinoda, Takashi Takahashi, Y. Yatabe (2005)
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 11
M. Tsao, A. Sakurada, J. Cutz, Chang-Qi Zhu, S. Kamel‐Reid, J. Squire, I. Lorimer, Tong Zhang, Ni Liu, M. Daneshmand, P. Marrano, G. Santos, A. Lagarde, F. Richardson, L. Seymour, M. Whitehead, K. Ding, J. Pater, F. Shepherd (2005)
Erlotinib in lung cancer - molecular and clinical predictors of outcome.The New England journal of medicine, 353 2
J. Paez, P. Jänne, Jeffrey Lee, Sean Tracy, H. Greulich, S. Gabriel, P. Herman, F. Kaye, N. Lindeman, T. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. Eck, W. Sellers, B. Johnson, M. Meyerson (2004)
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 304
R. Perez-soler (2004)
The Role of Erlotinib (Tarceva, OSI 774) in the Treatment of Non-Small Cell Lung CancerClinical Cancer Research, 10
F. Cappuzzo, F. Hirsch, E. Rossi, S. Bartolini, G. Ceresoli, L. Bemis, J. Haney, S. Witta, K. Danenberg, I. Domenichini, V. Ludovini, E. Magrini, V. Gregorc, C. Doglioni, A. Sidoni, M. Tonato, W. Franklin, L. Crinò, P. Bunn, M. Varella-Garcia (2005)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.Journal of the National Cancer Institute, 97 9
N. Thatcher, A. Chang, P. Parikh, J. Pereira, T. Ciuleanu, J. Pawel, S. Thongprasert, E. Tan, K. Pemberton, V. Archer, K. Carroll (2005)
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 366
Paz-Ares (2006)
A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients with mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR)Proc Annu Meet Am Assoc Cancer Res, 24
L. Paz-Ares, J. Sánchez, A. García-Velasco, B. Massutí, G. López-Vivanco, Mariano Provencio, A. Montes, Dolores Isla, M. Amador, R. Rosell (2006)
A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
T. Lynch, D. Bell, Raffaella Sordella, S. Gurubhagavatula, R. Okimoto, Brian Brannigan, Patricia Harris, Sara Haserlat, J. Supko, F. Haluska, D. Louis, D. Christiani, J. Settleman, D. Haber (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.The New England journal of medicine, 350 21
M. Kris, R. Natale, R. Herbst, T. Lynch, D. Prager, C. Belani, J. Schiller, K. Kelly, H. Spiridonidis, A. Sandler, K. Albain, D. Cella, M. Wolf, S. Averbuch, J. Ochs, A. Kay (2003)
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.JAMA, 290 16
Jing Yang, Sendurai Mani, J. Donaher, Sridhar Ramaswamy, R. Itzykson, C. Côme, P. Savagner, I. Gitelman, A. Richardson, R. Weinberg (2004)
Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor MetastasisCell, 117
C. Garnis, W. Lockwood, E. Vucic, Yong-sheng Ge, L. Girard, J. Minna, A. Gazdar, S. Lam, C. MacAulay, W. Lam (2006)
High resolution analysis of non‐small cell lung cancer cell lines by whole genome tiling path array CGHInternational Journal of Cancer, 118
W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, Bhuvanesh Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, Doris Kupfer, R. Wilson, M. Kris, H. Varmus (2004)
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.Proceedings of the National Academy of Sciences of the United States of America, 101 36
M. Cohen, Grant Williams, R. Sridhara, Gang Chen, W. Mcguinn, D. Morse, S. Abraham, Atiqur Rahman, Chen Liang, R. Lostritto, A. Baird, R. Pazdur (2004)
United States Food and Drug Administration Drug Approval SummaryClinical Cancer Research, 10
L. Morrison, K. Jacobson, M. Friedman, J. Schroeder, J. Coon (2005)
Aberrant EGFR and Chromosome 7 Associate with Outcome in Laryngeal CancerThe Laryngoscope, 115
H. Shin, D. Shin, E. Tarco, N. Sneige (2003)
Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesotheliomaCancer Cytopathology, 99
M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, J. Douillard, Y. Nishiwaki, J. Vansteenkiste, S. Kudoh, D. Rischin, R. Eek, T. Horai, K. Noda, I. Takata, E. Smit, S. Averbuch, A. Macleod, A. Feyereislova, R. Dong, J. Baselga (2003)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 12
H. Endoh, Y. Yatabe, T. Kosaka, H. Kuwano, T. Mitsudomi (2006)
PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer PatientsJournal of Thoracic Oncology, 1
R. Perez-soler, A. Chachoua, L. Hammond, E. Rowinsky, M. Huberman, D. Karp, J. Rigas, G. Clark, P. Santabarbara, P. Bonomi (2004)
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 16
Sae-Won Han, Tae-You Kim, Y. Jeon, P. Hwang, S. Im, Kyung-Hun Lee, J. Kim, Dong-Wan Kim, D. Heo, N. Kim, D. Chung, Y. Bang (2006)
Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt PhosphorylationClinical Cancer Research, 12
Bradley Coe, Eric Lee, Bryan Chi, L. Girard, J. Minna, A. Gazdar, S. Lam, C. MacAulay, W. Lam (2006)
Gain of a region on 7p22.3, containing MAD1L1, is the most frequent event in small‐cell lung cancer cell linesGenes, 45
D. Bell, T. Lynch, Sara Haserlat, Patricia Harris, R. Okimoto, Brian Brannigan, D. Sgroi, B. Muir, M. Riemenschneider, R. Iacona, A. Krebs, David Johnson, G. Giaccone, R. Herbst, C. Manegold, M. Fukuoka, M. Kris, J. Baselga, J. Ochs, D. Haber (2005)
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 31
F. Hirsch, M. Varella-Garcia, P. Bunn, Michael Maria, R. Veve, Roy Bremmes, A. Baron, C. Zeng, W. Franklin (2003)
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 20
ORIGINAL ARTICLE The Prognostic Value of Chromosome 7 Polysomy in Non-small Cell Lung Cancer Patients Treated with Gefitinib Lela E. Buckingham, PhD,* John S. Coon, MD, PhD,* Larry E. Morrison, PhD,† Kristine K. B. Jacobson, MSc,† Susan S. Jewell, PhD,† Kelly A. Kaiser, BSc,* Ann M. Mauer, MD,‡ Tariq Muzzafar, MD,‡ Clayton Polowy, MD,* Sanjib Basu, PhD,* Meryl Gale, MSc,* Victoria M. Villaflor, MD,* and Philip Bonomi, MD* with EGFR tyrosine kinase inhibitors is warranted in developing a Introduction: Specific subpopulations of non-small cell lung cancer clinical test for selecting patients for gefitinib therapy. (NSCLC) patients defined by clinical features and molecular profiles Key Words: Non-small cell, Targeted therapy, Molecular biomar- seem to derive greater benefit from epidermal growth factor receptor kers, Aneusomy, EGFR mutations. (EGFR) tyrosine kinase inhibitors, but no general consensus on molecular testing to optimize treatment has emerged. The objective (J Thorac Oncol. 2007;2: 414–422) of this study was to evaluate chromosome 7 polysomy and other potential indicators of gefitinib efficacy in advanced NSCLC pa- tients. n phase II trials, gefitinib (Iressa, AstraZeneca), a small Methods: Paraffin-embedded tumors from 82 patients treated with Imolecular tyrosine kinase inhibitor (TKI), demonstrated gefitinib were analyzed by immunohistochemistry for expression
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: May 1, 2007
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.